U.S. Foodand Drug AdministrationtodayapprovedInlyta (axitinib)for the treatment ofpatients withadvancedkidney cancer(renal cell carcinoma) and those whodid not respond toanother drugfor this type ofcancer.
Renal cell carcinomais a type ofkidney cancerthat startsin the lining ofverysmall tubesin the kidneys.Inlytaworks by blockingcertain proteinscalledkinasesthat playa role intumor growth and
Renal cell carcinomais a type ofkidney cancerthat startsin the lining ofverysmall tubesin the kidneys.Inlytaworks by blockingcertain proteinscalledkinasesthat playa role intumor growth and